Genomic Assays in the “Real” Oncology World: Exploring the Role of Genomic Testing in Guiding Treatment for Patients with Advanced Breast, Colorectal and Prostate Cancers


Module 1: Multiplex Genomic Assays and Their Role in Therapeutic Decision-Making

Track 1: Case: A man in his mid-80s with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed through multiple therapies is found to have CD274 (PD-L1) amplification, microsatellite instability (MSI)-high status and mutations in ATM and EGFR
Track 2: Effect of CD274 amplification on response to immune checkpoint inhibitors; activity of PARP inhibitors in patients with ATM mutations
Track 3: Advantages and limitations of multiplex genomic testing
Track 4: Role of serial testing to identify variations in genomic mutations or aberrations over time; potential benefit of liquid next-generation sequencing (NGS) panels
Track 5: Use of multiplex genomic assays by community oncologists and implications for clinical practice
Track 6: Optimal timing of genetic testing for patients diagnosed with metastatic disease
Track 7: Presentation (Dr McKenzie): Overview of multiplex genomic assay methodology
Track 8: Rationale for the use of serial testing and liquid assays to identify variations in genomic mutations or aberrations over time
Track 9: Differentiating between germline and somatic mutations in cancer tissue
Track 10: Perspective on the use of tissue versus liquid biopsy for genetic testing
Track 11: Sensitivity of liquid biopsies in detecting tumor mutations
Track 12: Available data exploring the impact of NGS use on patient outcomes
Track 13: Selection of a multiplex genomic assay for detecting genetic alterations
Track 14: Implications of multiplex genomic assay results for therapeutic decision-making

Module 2: Comprehensive Genetic Profiling and Precision Medicine for Metastatic Colorectal Cancer (mCRC)

Track 15: Specific biomarkers and genetic alterations routinely evaluated in clinical practice
Track 16: Effects of up-front multiplex genomic assay testing on outcomes for patients with mCRC
Track 17: Response to immune checkpoint inhibitors in patients with MSI-high mCRC
Track 18: Presentation (Dr Bendell): Biomarker assessment in mCRC; role of multiplex testing
Track 19: Actionable genetic alterations in mCRC; detection of BRAF and HER2 mutations and implications for practice
Track 20: Rationale and indications for the assessment of MSI and DNA mismatch repair (MMR) status; emerging role of tumor mutational burden
Track 21: Role of liquid versus tumor biopsies for detecting genetic alterations
Track 22: MSI/MMR and tumor mutational burden as predictors of benefit from immune checkpoint inhibitors
Track 23: Emerging role for the assessment of neoantigen load
Track 24: Case (Dr Bendell): A man in his mid-50s with mCRC, Lynch syndrome and MSI-high status achieves a partial response to pembrolizumab as second-line therapy
Track 25: Case (Dr Bendell): A woman in her early 60s with microsatellite stable mCRC and a BRAF V600E mutation receives the combination of cetuximab, encorafenib and binimetinib after disease progression on FOLFOXIRI/bevacizumab
Track 26: Case (Dr Bendell): A man in his early 40s with HER2-positive mCRC receives trastuzumab and pertuzumab on a clinical trial after disease progression on FOLFIRI/bevacizumab and attains a partial response
Track 27: Novel HER2-targeted therapies under evaluation for patients with mCRC and HER2 alterations
Track 28: Analysis of the gut microbiome and strategies to enhance the immune response to cancer

Module 3: NGS for Metastatic Prostate Cancer (mPC) and the Potential Clinical Significance of Genomic Alterations

Track 29: Genetic alterations assessed in routine practice, including MSI status, BRCA mutations and AR-V7 variants; role of multiplex testing
Track 30: Presentation (Dr Antonarakis): Biomarker assessment in mPC; detection of DNA damage repair abnormalities and prediction of benefit with PARP and PD-1 inhibitors
Track 31: Landscape of DNA damage repair mutations in newly diagnosed and metastatic prostate cancer
Track 32: Rationale for the use of PARP inhibitors for prostate cancer with BRCA or ATM mutations
Track 33: Genetic testing of primary and metastatic tumors for alterations in the DNA repair and androgen receptor (AR) signaling pathways
Track 34: Clinical significance and genetic detection of AR splice variants
Track 35: Results of the CARD trial: Cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experience rapid disease progression on an AR-targeted agent
Track 36: Efficacy of olaparib for mCRPC
Track 37: Available data with rucaparib, niraparib and talazoparib for mCRPC
Track 38: Role of radium-223 dichloride for patients with mPC; novel combination approaches with radium-223 under investigation
Track 39: Sensitivity of BRCA1, BRCA2 and ATM mutations to PARP inhibitors
Track 40: Activity of PARP inhibitors in patients with breast, ovarian, prostate and pancreatic cancers with BRCA mutations
Track 41: Homologous recombination deficiency and response to PARP inhibitors
Track 42: Case (Dr Antonarakis): A man in his mid-40s with mCRPC and a BRCA2 mutation attains a complete response to olaparib
Track 43: Case (Dr Antonarakis): A man in his mid-60s diagnosed with de novo mPC and MSI-high status, high tumor mutation burden and an MSH2 mutation experiences an excellent response to pembrolizumab after multiple lines of therapy
Track 44: Association of ductal and intraductal prostate cancer with a high prevalence of DNA damage repair gene mutations
Track 45: Predictors of benefit with immune checkpoint inhibitors

MODULE 4: Multigene Testing and Detection of Genomic Alterations in Metastatic Breast Cancer (mBC)

Track 46: Role of MSI testing and multiplex genomic assays in mBC
Track 47: Assessment of PIK3CA and BRCA mutations and assays for ESR1
Track 48: Presentation (Dr Krop): Biomarker assessment in mBC — ER-positive and triple-negative disease
Track 49: PTEN loss and implications for therapeutic decision-making for mBC
Track 50: ESR1 mutations and resistance to hormone therapy
Track 51: Efficacy of PARP inhibitors in patients with BRCA mutations
Track 52: HER2 expression in HER2 nonamplified cancers; activity of trastuzumab deruxtecan in HER2-low breast cancer
Track 53: PD-L1 and other biomarkers predictive of benefit from immunotherapy in triple-negative breast cancer (TNBC)
Track 54: Case (Dr Krop): A woman in her late 50s with de novo TNBC receives atezolizumab/nab paclitaxel as first-line therapy
Track 55: Case (Dr Krop): A woman in her early 60s with ER-positive, HER2-negative mBC and a germline BRCA2 mutation whose disease progresses through multiple therapies attains a partial response to olaparib

MODULE 5: The Sarah Cannon Experience with Molecular Tumor Boards

Track 56: The use of molecular tumor boards to review molecular profiling data and facilitate therapeutic decision-making
Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel
Comprehensive Cancer Center
Baltimore, Maryland
Johanna Bendell, MD
Chief Development Officer
Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Ian E Krop, MD, PhD
Associate Chief
Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Andrew McKenzie, PhD
Senior Manager, Personalized Medicine
Sarah Cannon Research Institute
Nashville, Tennessee
Neil Love, MD
Research To Practice
Miami, Florida